NCT00182637View on ClinicalTrials.gov

Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions
Lymphoma
Interventions
DRUG

bortezomib

Trial Locations (1)

90095-1781

Jonsson Comprehensive Cancer Center at UCLA, Los Angeles

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

Jonsson Comprehensive Cancer Center

OTHER